Pipeline Overview
Product Candidate | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Market | ||
---|---|---|---|---|---|---|---|---|
Virology: Liver | ||||||||
HCV | Protease Inhibitor | Glecaprevir (part of pangenotypic, 2-DAA combo) | ||||||
HBV | Core Inhibitor | |||||||
Virology: Respiratory | ||||||||
RSV | N-Protein Inhibitor | EDP-938 RSVPEDs | ||||||
EDP-938 RSVTx | ||||||||
EDP-938 RSVHR | ||||||||
L-Protein Inhibitor | EDP-323 | |||||||
Dual hMPV/RSV | Non-Fusion Inhibitor | |||||||
COVID-19 | Protease Inhibitor | EDP-235 SPRINT | ||||||
3CL PL Protease Inhibitor | ||||||||
For Out-Licensing | ||||||||
NASH | FXR Agonists | EDP-305 (Phase 2), EDP-297 (Phase 1) |
Virology: Liver | |||||
---|---|---|---|---|---|
HCV Protease Inhibitor | |||||
Discovery | Preclin | Phase 1 | Phase 2 | Phase 3 | Market |
Glecaprevir (part of pangenotypic, |
|||||
HBV Core Inhibitor | |||||
Discovery | Preclin | Phase 1 | Phase 2 | Phase 3 | Market |
EDP-514 |
Virology: Respiratory | |||||
---|---|---|---|---|---|
RSV N-Protein Inhibitor | |||||
Discovery | Preclin | Phase 1 | Phase 2 | Phase 3 | Market |
EDP-938 RSVPEDs |
|||||
RSV N-Protein Inhibitor | |||||
Discovery | Preclin | Phase 1 | Phase 2 | Phase 3 | Market |
EDP-938 RSVTx |
|||||
RSV N-Protein Inhibitor | |||||
Discovery | Preclin | Phase 1 | Phase 2 | Phase 3 | Market |
EDP-938 RSVHR |
|||||
RSV L-Protein Inhibitor | |||||
Discovery | Preclin | Phase 1 | Phase 2 | Phase 3 | Market |
EDP-323 |
|||||
Dual hMPV/RSV Non-Fusion Inhibitor | |||||
Discovery | Preclin | Phase 1 | Phase 2 | Phase 3 | Market |
|
|||||
COVID-19 3CL PL Protease Inhibitor | |||||
Discovery | Preclin | Phase 1 | Phase 2 | Phase 3 | Market |
EDP-235 SPRINT |
|||||
COVID-19 PL Protease Inhibitor | |||||
Discovery | Preclin | Phase 1 | Phase 2 | Phase 3 | Market |
|
For Out-Licensing | |||||
---|---|---|---|---|---|
NASH FXR Agonists | |||||
Discovery | Preclin | Phase 1 | Phase 2 | Phase 3 | Market |
EDP-305 (Phase 2), EDP-297 (Phase 1) |
*Fixed-dose combination contains glecaprevir and AbbVie's NS5A inhibitor, pibrentasvir. Marketed by AbbVie as MAVYRET (U.S.) and MAVIRET (ex-U.S.).